Bioniz Therapeutics reports positive phase 1/2 trial data for BNZ-1 in treating relapsed/refractory CTCL

Bioniz Therapeutics, a leading player in the field of peptide-based therapeutics, has revealed promising data from a phase 1/2 clinical trial of its drug candidate ... Read More